Citation map · Study

SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework

16 references·5 citing·38 second hop

FromToDepth

this work references cited by second hop

References

2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement83,813 cited
2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.44,857 cited
2005Scoping studies: towards a methodological framework36,603 cited
2002Qualitative data analysis for applied policy research4,965 cited
2010Qualitative data analysis for applied policy research4,799 cited
2002Analyzing Qualitative Data1,446 cited
2008The NICE Cost-Effectiveness Threshold868 cited
2001Synthesising research evidence.439 cited
2002Evidence-based Policy: In Search of a Method403 cited
2007Assessing the economic challenges posed by orphan drugs279 cited
2011Pricing and reimbursement of orphan drugs: the need for more transparency261 cited
2012The High Cost of Cancer Drugs and What We Can Do About It255 cited
2011Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer230 cited
2008Value based pricing for NHS drugs: an opportunity not to be missed?230 cited
2005Orphan drugs and the NHS: should we value rarity?229 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2005Drugs for exceptionally rare diseases: do they deserve special status for funding?220 cited

Cited by

2017HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries83 cited
2016Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries82 cited
2017DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS82 cited
2015Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation77 cited
2018Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?76 cited